We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04198922
Recruitment Status : Recruiting
First Posted : December 13, 2019
Last Update Posted : November 28, 2022
Information provided by (Responsible Party):
Fred Hutchinson Cancer Center

Brief Summary:
This phase II trial studies how well acalabrutinib works in treating patients with chronic graft versus host disease. Acalabrutinib may be an effective treatment for graft-versus-host disease caused by a stem cell transplant.

Condition or disease Intervention/treatment Phase
Recurrent Moderate-Severe Chronic Graft Versus Host Disease Hematopoietic and Lymphoid Cell Neoplasm Drug: Acalabrutinib Other: Questionnaire Administration Phase 2

Detailed Description:


Patients receive acalabrutinib orally (PO) twice daily (BID) on days 1-28. Treatment repeats every 28 days for up to 6 cycles with an option to continue for up to 24 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days and then periodically thereafter.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Acalabrutinib for Chronic Graft-Versus-Host Disease
Actual Study Start Date : December 12, 2020
Estimated Primary Completion Date : January 31, 2025
Estimated Study Completion Date : January 31, 2027

Arm Intervention/treatment
Experimental: Treatment (acalabrutinib)
Patients receive acalabrutinib 100 mg PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles with an option to continue for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
Drug: Acalabrutinib
Given PO
Other Names:
  • 1420477-60-6
  • ACP-196
  • Benzamide
  • Bruton Tyrosine Kinase Inhibitor ACP-196
  • Calquence

Other: Questionnaire Administration
Ancillary studies

Primary Outcome Measures :
  1. Best response (complete and partial response [CR + PR]) [ Time Frame: Within the first 6 months of treatment when the best response rate is known for each patient ]
    The composite outcome of CR and PR, calculated according to the proposed response definitions of the 2014 National Institutes of Health Consensus Conference. Exact 95% confidence intervals (CI) will be calculated for the objective response rate using the Clopper and Pearson method. Will also compare the observed best ORR with the published efficacy of ibrutinib (67%) and provide the 95% CI for the difference.

Secondary Outcome Measures :
  1. Incidence of adverse events (AEs) [ Time Frame: Up to 30 days following the last dose of acalabrutinib ]
    Defined as grade 3 and above according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 and all serious AEs (SAEs) described for the population receiving at least one dose of acalabrutinib at least from the time of consent through the safety follow-up period. Any AE/SAE at least possibly related to acalabrutinib therapy will be reported for the duration of the study.

  2. Duration of response (DOR) [ Time Frame: From the date the PR is documented until loss of the response or start of another systemic immunosuppressive treatment for chronic graft versus host disease (GVHD), whichever occurs first, assessed up to 3 years ]
    Will be described for the group achieving at least a PR, defined as the number of weeks the subject maintains a PR or CR. Will be estimated using the Kaplan-Meier method. Approximate 95% CIs for median DOR will be computed using the formula proposed by Brookmeyer and Crowley.

  3. Change in patient-reported outcomes: Lee Chronic GVHD Symptom Scale score [ Time Frame: Baseline up to 3 years ]
    Will be assessed by the Lee Chronic GVHD Symptom Scale score. Scores will be calculated based on published algorithms with absolute changes and clinically meaningful changes described for the population as a whole and based on CR + PR versus stable disease (SD) + mixed response (MR) + progressive disease (PD).

  4. Change in patient-reported outcomes: Patient-Reported Outcomes Measurement Information System-29 [ Time Frame: Baseline up to 3 years ]
    Will be assessed by the Patient-Reported Outcomes Measurement Information System-29. Scores will be calculated based on published algorithms with absolute changes and clinically meaningful changes described for the population as a whole and based on CR + PR versus stable disease (SD) + mixed response (MR) + progressive disease (PD).

  5. Failure-free survival [ Time Frame: At 6 months and 1 year ]
    Will be defined as the duration of relapse-free survival without adding any other systemic treatment for chronic GVHD. Will be estimated with the composite event of death from any cause, relapse and addition of secondary immune suppressive agents using the Kaplan-Meier method. Systemic immune-suppressive agents include orally or intravenously administered systemically active immune-suppressive drugs, as well as procedures including extra-corporeal photopheresis.

  6. Organ-specific response rates [ Time Frame: Up to 3 years ]
    Response rates by organ will also be calculated and reported as ORR (CR+PR) versus all other categories (SD, PD, MR).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Moderate-severe chronic GVHD, diagnosed per the 2014 National Institutes of Health (NIH) criteria
  • Progression or recurrence of active chronic GVHD signs/symptoms after treatment with steroids
  • Presence of at least one of these manifestations: skin erythema, mouth sensitivity or ulcers, nausea, diarrhea or liver dysfunction attributable to chronic GVHD
  • Karnofsky performance status >= 70%
  • Woman of childbearing potential (WOCBP) who are sexually active must use highly effective methods of contraception during treatment and for 2 days after the last dose of acalabrutinib
  • Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty
  • Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information

Exclusion Criteria:

  • Hospitalization for evaluation or management of an infection within the last 8 weeks
  • Change in immunosuppressive regimen within the 2 weeks prior to enrollment
  • Noncompliance
  • Treatment of chronic GVHD with ibrutinib
  • Recurrent or prior malignancy (or any other malignancy that requires active treatment), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for >= 2 years
  • Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any class 3 or 4 cardiac disease as defined by the New York Heart Association functional classification. Subjects with controlled, asymptomatic atrial fibrillation during screening can enroll on study
  • Has difficulty with or is unable to swallow oral medication, or has significant gastrointestinal disease that would limit absorption of oral medication
  • Known history of infection with human immunodeficiency virus (HIV)
  • Uncontrolled, active significant infection (e.g., bacterial, viral, fungal or progressive multifocal leukoencephalopathy)
  • Known history of drug-specific hypersensitivity or anaphylaxis to study drug (including active product or excipient components)
  • Active bleeding, history of bleeding diathesis (e.g., hemophilia or von Willebrand disease)
  • Uncontrolled AIHA (autoimmune hemolytic anemia) or ITP (idiopathic thrombocytopenic purpura)
  • Requires treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor/inducer
  • Requires or receiving therapeutic anti-platelet or anticoagulation, including warfarin or equivalent vitamin K antagonist
  • Prothrombin time/international normalized ratio (INR) or activated partial thromboplastin time (aPTT) (in the absence of lupus anticoagulant) > 2 x upper limit of normal (ULN)
  • Requires treatment with proton pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Subjects receiving proton pump inhibitors who switch to H2-receptor antagonists or antacids are eligible for enrollment to this study
  • History of significant cerebrovascular disease or event, including stroke or intracranial hemorrhage, within 6 months before the first dose of study drug
  • Major surgical procedure within 28 days of first dose of study drug. Note: If a subject had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug
  • Subjects who are hepatitis B core antibody (anti-HBc) positive and who are surface antigen negative will need to have a negative polymerase chain reaction (PCR). Those who are hepatitis B surface antigen (HBsAg) positive or hepatitis B PCR positive will be excluded. Subjects who are hepatitis C antibody positive will need to have a negative PCR result. Those who are hepatitis C PCR positive will be excluded
  • Child-Pugh score of C for hepatic impairment
  • Absolute neutrophil count < 1.0 x 10^9/L or use of myeloid growth factors within the past 2 weeks
  • Platelet count < 50 x 10^9/L or platelet transfusion or thrombomimetic agent within the past 2 weeks
  • Total bilirubin > 2 mg/dL or alanine aminotransferase (ALT) > 2 x upper limit of normal, unless abnormalities are due to liver GVHD, in which case total bilirubin > 3 mg/dL or ALT 5 x upper limit of normal are exclusions
  • Glomerular filtration rate < 50 mL/min/1.73 m^2
  • Breastfeeding or pregnant
  • Concurrent participation in another clinical trial and receiving a non-Food and Drug Administration (FDA) approved medication

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04198922

Layout table for location contacts
Contact: Peter Fatland 206.667.6830 chronicGVHDstudies@fredhutch.org

Layout table for location information
United States, Florida
Moffitt Cancer Center Recruiting
Tampa, Florida, United States, 33612
Contact: Joseph Pidala    813-745-2556    joseph.pidala@moffitt.org   
Principal Investigator: Joseph Pidala, MD, PhD         
United States, New York
Roswell Park Comprehensive Cancer Center Active, not recruiting
Buffalo, New York, United States, 14203
United States, Ohio
The Ohio State University Wexner Medical Center Recruiting
Columbus, Ohio, United States, 43210
Contact: Maurice Austin    614-929-9526    Maurice.Austin@osumc.edu   
Principal Investigator: Hannah K. Choe, MD         
United States, Tennessee
Vanderbilt University Medical Center Recruiting
Nashville, Tennessee, United States, 37212
Contact: Carrie Kitko    615-936-1762    carrie.l.kitko@vumc.edu   
Principal Investigator: Carrie Kitko, MD         
United States, Texas
The University of Texas MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Anna E. Kratz    855-220-4587    aekratz@mdanderson.org   
Principal Investigator: Rohtesh Mehta, MD, MPH, MS         
United States, Washington
Fred Hutch/University of Washington Cancer Consortium Recruiting
Seattle, Washington, United States, 98109
Contact: Peter Fatland    206-667-6830    chronicGVHDstudies@fredhutch.org   
Principal Investigator: Stephanie Lee, MD, MPH         
Sponsors and Collaborators
Fred Hutchinson Cancer Center
Layout table for investigator information
Principal Investigator: Stephanie Lee Fred Hutch/University of Washington Cancer Consortium
Layout table for additonal information
Responsible Party: Fred Hutchinson Cancer Center
ClinicalTrials.gov Identifier: NCT04198922    
Other Study ID Numbers: RG1006135
NCI-2019-06980 ( Registry Identifier: NCI / CTRP )
8801 ( Other Identifier: Fred Hutch/University of Washington Cancer Consortium )
First Posted: December 13, 2019    Key Record Dates
Last Update Posted: November 28, 2022
Last Verified: October 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Graft vs Host Disease
Immune System Diseases
Antineoplastic Agents